Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 42 min ago
Peer-reviewedCC BY 4.0The American Journal of Tropical Medicine and Hygiene

Management of Bullous Pemphigoid and Norwegian Scabies with Dupilumab Plus Ivermectin

  • Yanli Zhang1
  • Yuting Liu2
  • Hengan Yi1,3
  1. 1Department of Dermatology, The Third People’s Hospital of Longgang, Clinical Institute of Shantou University Medical College (The Third People’s Hospital of Longgang District Shenzhen), Shenzhen, China
  2. 2Department of Dermatology, Shenzhen People’s Hospital (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, China
  3. 3Department of Dermatology, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen, China
Read full textDOICite

Abstract

Bullous pemphigoid is a severe autoimmune blistering disease, and Norwegian scabies is a rare comorbidity. However, conventional treatment methods, such as systemic corticosteroids, carry a high risk in the treatment of elderly patients. Herein, this rare comorbidity is described in an elderly patient. After an initial induction treatment with a low-to-moderate dose of corticosteroid, this patient achieved complete remission with a combination therapy of dupilumab (a monoclonal antibody targeting the interleukin-4/13 signaling pathway) and ivermectin. Therefore, the successful treatment of this rare case provides a promising strategy for reducing reliance on corticosteroids in high-risk populations.

Related

  1. Use of dupilumab for localized bullous pemphigoid in an elderly indigenous woman residing in a Nunavik elders’ home: A case report
    Meghan Kanou MD, Vinesh Rao BS, Roy Khalaf MD +1
    SAGE Open Medical Case ReportsPeer-reviewedCC BYFull textGeneral medicineDOAJ
  2. Deucravacitinib in concomitant psoriasis vulgaris and bullous pemphigoid: A case of sustained dual disease control
    Rachel Daher, Alessandro Magnatta, Walter Volpi +7
    JAAD case reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Long-term upadacitinib treatment in a patient with atopic dermatitis, bullous pemphigoid, and alopecia areata: a case report and review of the literature
    Sara Triolo, Manfredo Bruni, Lina Maria Magnanimi +5
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. [Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report].
    Sourdeau É, Clauser S, Prud'Homme R +2
    Annales de Biologie CliniquePeer-reviewedCC BY-NC-NDFull text6 citedGeneral biologyGeneral medicineHAL
  5. Research Progress on Targeted Therapies for Pemphigus Vulgaris and Bullous Pemphigoid: Mechanisms, Opportunities and Challenges
    Wang-Fei Mo, Ya-Gang Zuo
    International journal of molecular sciencesPeer-reviewedCC BYFull textGeneral medicineEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{zhang2026management,
  title = {{Management of Bullous Pemphigoid and Norwegian Scabies with Dupilumab Plus Ivermectin}},
  author = {Yanli Zhang and Yuting Liu and Hengan Yi},
  journal = {The American Journal of Tropical Medicine and Hygiene},
  year = {2026},
  month = sep,
  doi = {10.4269/ajtmh.26-0186},
  url = {https://doi.org/10.4269/ajtmh.26-0186},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Management of Bullous Pemphigoid and Norwegian Scabies with Dupilumab Plus Ivermectin
AU  - Yanli Zhang
AU  - Yuting Liu
AU  - Hengan Yi
PY  - 2026
DA  - 2026/09/22
JO  - The American Journal of Tropical Medicine and Hygiene
DO  - 10.4269/ajtmh.26-0186
UR  - https://doi.org/10.4269/ajtmh.26-0186
AB  - Bullous pemphigoid is a severe autoimmune blistering disease, and Norwegian scabies is a rare comorbidity. However, conventional treatment methods, such as systemic corticosteroids, carry a high risk in the treatment of elderly patients. Herein, this rare comorbidity is described in an elderly patient. After an initial induction treatment with a low-to-moderate dose of corticosteroid, this patient achieved complete remission with a combination therapy of dupilumab (a monoclonal antibody targeting the interleukin-4/13 signaling pathway) and ivermectin. Therefore, the successful treatment of this rare case provides a promising strategy for reducing reliance on corticosteroids in high-risk populations.
SN  - 0002-9637
SN  - 1476-1645
ER  -